Goldman Sachs Issues Buy Rating for Mobia Medical, Foresees Potential for Share Price to Double

Deep News

Jun 02

Goldman Sachs has indicated that the share price of Mobia Medical could more than double as the company advances in an underserved segment of the stroke rehabilitation market.

The investment bank initiated coverage on this developer of neurostimulation therapies with a "Buy" rating and set a price target of $31. This target implies an upside potential of approximately 130% from Monday's closing price.

Mobia Medical (ASX: MOBI)

Analyst David Roman stated in a client report that, based on the company's innovative neurostimulation technology, the expansive market opportunity, the historical performance of comparable (small to mid-sized) medical technology companies in pioneering markets, and the anticipated revenue trajectory, the stock is emerging as a differentiated growth asset.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1157970078"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1157970078\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1157970078?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157970078","market":"sh","top_or_hot":-1,"title":"Goldman Sachs Issues Buy Rating for Mobia Medical, Foresees Potential for Share Price to Double","media":"Deep News","content":"<p>Goldman Sachs has indicated that the share price of Mobia Medical could more than double as the company advances in an underserved segment of the stroke rehabilitation market.<br><br>The investment bank initiated coverage on this developer of neurostimulation therapies with a \"Buy\" rating and set a price target of $31. This target implies an upside potential of approximately 130% from Monday's closing price.<br><br><b>Mobia Medical (ASX: MOBI)</b><br><br>Analyst David Roman stated in a client report that, based on the company's innovative neurostimulation technology, the expansive market opportunity, the historical performance of comparable (small to mid-sized) medical technology companies in pioneering markets, and the anticipated revenue trajectory, the stock is emerging as a differentiated growth asset.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs Issues Buy Rating for Mobia Medical, Foresees Potential for Share Price to Double</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs Issues Buy Rating for Mobia Medical, Foresees Potential for Share Price to Double\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-06-02 21:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Goldman Sachs has indicated that the share price of Mobia Medical could more than double as the company advances in an underserved segment of the stroke rehabilitation market.<br><br>The investment bank initiated coverage on this developer of neurostimulation therapies with a \"Buy\" rating and set a price target of $31. This target implies an upside potential of approximately 130% from Monday's closing price.<br><br><b>Mobia Medical (ASX: MOBI)</b><br><br>Analyst David Roman stated in a client report that, based on the company's innovative neurostimulation technology, the expansive market opportunity, the historical performance of comparable (small to mid-sized) medical technology companies in pioneering markets, and the anticipated revenue trajectory, the stock is emerging as a differentiated growth asset.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"","article_id":"1157970078","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157970078","pubTimestamp":1780405720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Goldman Sachs has indicated that the share price of Mobia Medical could more than double as the company advances in an underserved segment of the stroke rehabilitation market.The investment bank...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","MOBI":"Mobia Medical"},"translate_title":"高盛对Mobia Medical给予买入评级，预计股价可能翻倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MOBI":1},"content_text":"Goldman Sachs has indicated that the share price of Mobia Medical could more than double as the company advances in an underserved segment of the stroke rehabilitation market.The investment bank initiated coverage on this developer of neurostimulation therapies with a \"Buy\" rating and set a price target of $31. This target implies an upside potential of approximately 130% from Monday's closing price.Mobia Medical (ASX: MOBI)Analyst David Roman stated in a client report that, based on the company's innovative neurostimulation technology, the expansive market opportunity, the historical performance of comparable (small to mid-sized) medical technology companies in pioneering markets, and the anticipated revenue trajectory, the stock is emerging as a differentiated growth asset.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}